A biopharmaceutical is a therapeutic drug manufactured in, extracted from, or semi-synthesized from biological sources. Biopharmaceuticals include a wide range of products such as vaccines, therapeutic proteins, blood and blood components, tissues, etc. Biopharmaceuticals are among the most sophisticated and elegant achievements of modern science.

Market Dynamics:

Increasing burden of chronic, infectious, and neurological diseases, growing geriatric population, increase in research and development (R&D), and outbreak of COVID-19 (pandemic) are major factors expected to augment the growth of the global biopharmaceuticals market.

For instance, in October 2022, Phanes Therapeutics, Inc. received clearance from the US Food and Drug Administration (FDA) to commence Phase I studies with PT217, its anti-Delta-like ligand 3 (DLL3)/anti-Cluster of differentiation 47 (CD47) bispecific antibody being developed for patients with small cell lung cancer (SCLC) and other neuroendocrine cancer. PT217 recently been granted an orphan drug designation by the FDA for the treatment of SCLC.

Key features of the study:

• This report provides in-depth analysis of the global biopharmaceuticals market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global biopharmaceuticals market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Amgen Inc., GlaxoSmithKline PLC, Pfizer Inc., Novo Nordisk AS, Novartis AG, Johnson & Johnson, Eli Lilly and Company, Bristol-Myers Squibb Company, Abbvie Inc., and F. Hoffmann-La Roche Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global biopharmaceuticals market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global biopharmaceuticals market.

Detailed Segmentation:

• Global Biopharmaceuticals Market, By Product Type:
  • Monoclonal Antibodies
  • Recombinant Growth Factors
  • Purified Proteins
  • Recombinant Proteins
  • Recombinant Hormones
  • Vaccines
  • Recombinant Enzymes
  • Cell and Gene Therapies
  • Synthetic Immunomodulators
  • Other Product Types
• Global Biopharmaceuticals Market, By Therapeutic Application:
  • Oncology
  • Inflammatory and Infectious Diseases
  • Autoimmune Disorders
  • Metabolic Disorders
  • Hormonal Disorders
  • Cardiovascular Diseases
  • Neurological Diseases
  • Other Diseases
• Global Biopharmaceuticals Market, By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Amgen Inc.
  • Abbvie Inc.
  • GlaxoSmithKline PLC
  • Pfizer Inc.
  • Novo Nordisk AS
  • Novartis AG
  • Johnson & Johnson
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • F.Hoffmann-La Roche Ltd.